Skip to content
Lung Cancer Screening / Tobacco Control
Pulmonary – From Diagnostics to Therapeutics
Adjuvant/Neo-adjuvant Systemic Therapy
Surgery for Early-Stage NSCLC
Radiation in Early-Stage NSCLC
Locally Advanced NSCLC- Radiation Therapy
Locally Advanced NSCLC Chemotherapy / Targeted Therapy / Immunotherapy
Stage III NSCLC – Surgical/Combined Modality
Tumor Biology, Pathology, Novel Diagnostics
ALK, ROS1, and BRAF Positive Lung Cancer
EGFR Mutated Lung Cancer - Advanced Stage
Other Oncogene-Driven Cancers
PD-1/PD-L1 Directed Immunotherapy for Advanced NSCLC
Other Immunotherapy Targets & Agents- Advanced NSCLC
Mesothelioma and Thymoma – Limited and Advanced Stage
Statistical Considerations in Early Phase Clinical Trial Design in the Era of Targeted Therapy and Immunotherapy
PK and PD Considerations in Early Phase Clinical Trials
How I treat Stage III NSCLC
Immunotherapy in Cancer: Next Generation Biomarkers
Management of Immune Related Adverse Events
Progress in CAR-T Cell Therapies
Pancreatic Cancer: Emerging Strategies
Esophageal and Gastric Cancer: New Developments
Updates in Immunotherapy for Lung Cancer: Integration of Predictive Biomarkers
Post navigation
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Ok 
